Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8535030rdf:typepubmed:Citationlld:pubmed
pubmed-article:8535030lifeskim:mentionsumls-concept:C1272753lld:lifeskim
pubmed-article:8535030lifeskim:mentionsumls-concept:C0476089lld:lifeskim
pubmed-article:8535030lifeskim:mentionsumls-concept:C1514474lld:lifeskim
pubmed-article:8535030lifeskim:mentionsumls-concept:C1522326lld:lifeskim
pubmed-article:8535030lifeskim:mentionsumls-concept:C0868928lld:lifeskim
pubmed-article:8535030lifeskim:mentionsumls-concept:C0700085lld:lifeskim
pubmed-article:8535030pubmed:issue9lld:pubmed
pubmed-article:8535030pubmed:dateCreated1996-2-8lld:pubmed
pubmed-article:8535030pubmed:abstractTextFrom January 1, 1983 to December 31, 1990 two hundred and six patients with an invasive, non metastatic endometrial carcinoma were first treated at Institut Curie. Initial tumoral staging (TNM) was as follows: stage Ia: 48%, stage Ib: 31%, stage II: 15% and stage III-IV: 6%. Total hysterectomy or colpohysterectomy was performed in 186 cases, with a bilateral oophorectomy in 180 cases. Bilateral limited pelvic lymphadenectomy was performed in 116 cases. Brachytherapy was performed in the pre-operative setting in 25 cases, in the post-operative setting in 134 cases. Only five patients had brachytherapy alone, because of poor medical condition. External irradiation was exclusive in 15 cases and added to surgery for 68 patients. Median follow-up is 61 months (8-122 months). Five-year survival rate is 77% (71-83%); 5-year specific survival rate is 81% (75-87%). Independent prognostic factors for survival in multivariate analysis (Cox regression model) are tumoral stage (p < 0.0001), ovarian involvement (p < 0.0001), histologic node involvement (p = 0.005) and grade (p = 0.01). For local relapse, independent risk factors in the same analysis are ovarian involvement (p = 0.0004), tumoral stage (p = 0.01), age (p = 0.02) and histologic involvement of cervix (p = 0.04). For distant failure, independent risk factors are histologic node involvement (p = 0.0001), tumoral stage (p = 0.002) and grade (p = 0.003).lld:pubmed
pubmed-article:8535030pubmed:languagefrelld:pubmed
pubmed-article:8535030pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8535030pubmed:citationSubsetIMlld:pubmed
pubmed-article:8535030pubmed:statusMEDLINElld:pubmed
pubmed-article:8535030pubmed:monthSeplld:pubmed
pubmed-article:8535030pubmed:issn0007-4551lld:pubmed
pubmed-article:8535030pubmed:authorpubmed-author:ChewHHlld:pubmed
pubmed-article:8535030pubmed:authorpubmed-author:AsselainBBlld:pubmed
pubmed-article:8535030pubmed:authorpubmed-author:DurandJ CJClld:pubmed
pubmed-article:8535030pubmed:authorpubmed-author:FentonJJlld:pubmed
pubmed-article:8535030pubmed:authorpubmed-author:LabibAAlld:pubmed
pubmed-article:8535030pubmed:authorpubmed-author:de la...lld:pubmed
pubmed-article:8535030pubmed:authorpubmed-author:CloughKKlld:pubmed
pubmed-article:8535030pubmed:authorpubmed-author:Mouret-Fourme...lld:pubmed
pubmed-article:8535030pubmed:issnTypePrintlld:pubmed
pubmed-article:8535030pubmed:volume82lld:pubmed
pubmed-article:8535030pubmed:ownerNLMlld:pubmed
pubmed-article:8535030pubmed:authorsCompleteYlld:pubmed
pubmed-article:8535030pubmed:pagination717-23lld:pubmed
pubmed-article:8535030pubmed:dateRevised2009-11-11lld:pubmed
pubmed-article:8535030pubmed:meshHeadingpubmed-meshheading:8535030-...lld:pubmed
pubmed-article:8535030pubmed:meshHeadingpubmed-meshheading:8535030-...lld:pubmed
pubmed-article:8535030pubmed:meshHeadingpubmed-meshheading:8535030-...lld:pubmed
pubmed-article:8535030pubmed:meshHeadingpubmed-meshheading:8535030-...lld:pubmed
pubmed-article:8535030pubmed:meshHeadingpubmed-meshheading:8535030-...lld:pubmed
pubmed-article:8535030pubmed:meshHeadingpubmed-meshheading:8535030-...lld:pubmed
pubmed-article:8535030pubmed:meshHeadingpubmed-meshheading:8535030-...lld:pubmed
pubmed-article:8535030pubmed:meshHeadingpubmed-meshheading:8535030-...lld:pubmed
pubmed-article:8535030pubmed:meshHeadingpubmed-meshheading:8535030-...lld:pubmed
pubmed-article:8535030pubmed:meshHeadingpubmed-meshheading:8535030-...lld:pubmed
pubmed-article:8535030pubmed:meshHeadingpubmed-meshheading:8535030-...lld:pubmed
pubmed-article:8535030pubmed:meshHeadingpubmed-meshheading:8535030-...lld:pubmed
pubmed-article:8535030pubmed:meshHeadingpubmed-meshheading:8535030-...lld:pubmed
pubmed-article:8535030pubmed:meshHeadingpubmed-meshheading:8535030-...lld:pubmed
pubmed-article:8535030pubmed:meshHeadingpubmed-meshheading:8535030-...lld:pubmed
pubmed-article:8535030pubmed:meshHeadingpubmed-meshheading:8535030-...lld:pubmed
pubmed-article:8535030pubmed:year1995lld:pubmed
pubmed-article:8535030pubmed:articleTitle[Prognostic factors in endometrial cancer: apropos of 206 cases treated at the Curie Institute].lld:pubmed
pubmed-article:8535030pubmed:affiliationDépartement d'oncologie radiothérapique, Institut Curie, Paris, France.lld:pubmed
pubmed-article:8535030pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8535030pubmed:publicationTypeEnglish Abstractlld:pubmed